Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK

Journal of Medical Genetics

Volumn 48, Issue 4, 2011, Pages 266-272

  Cust, Anne E ^a   Harland, Mark ^b   Makalic, Enes ^a   Schmidt, Daniel ^a   Dowty, James G ^a   Aitken, Joanne F ^c   Agha Hamilton, Chantelle ^d   Armstrong, Bruce K ^e   Barrett, Jenny H ^b   Chan, May ^b   Chang, Yu Mei ^b   Gascoyne, Joanne ^b   Giles, Graham G ^a,f   Holland, Elizabeth A ^d   Kefford, Richard F ^d   Kukalizch, Kairen ^b   Lowery, Johanna ^g   Randerson Moor, Juliette A ^b   Schmid, Helen ^d   Taylor, Claire F ^h   Whitaker, Linda ^b   Hopper, John L ^a   Newton Bishop, Julia A ^b   Mann, Graham J ^d   Bishop, D Timothy ^b   Jenkins, Mark A ^a   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c VIERTEL CENTRE FOR RESEARCH IN CANCER CONTROL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f CANCER EPIDEMIOLOGY CENTRE   (Australia)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER RISK; EXON; FEMALE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MELANOMA; MISSENSE MUTATION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RADIATION EXPOSURE; RELATIVE; ULTRAVIOLET IRRADIATION; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CASE-CONTROL STUDIES; FEMALE; GENES, P16; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HETEROZYGOTE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; RISK ASSESSMENT;

EID: 79953704480     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2010.086538     Document Type: Article

References (23)

1. Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum Genet 2009;126:499-510.
2. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-6.
3. Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005;97:1507-15.
4. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
5. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
6. Hopper JL, Chenevix-Trench G, Jolley DJ, Dite GS, Jenkins MA, Venter DJ, McCredie MR, Giles GG. Design and analysis issues in a population-based, casecontrol-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr 1999;(26):95-100.
7. Scott CL, Jenkins MA, Southey MC, Davis TA, Leary JA, Easton DF, Phillips KA, Hopper JL. Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Hum Genet 2003;112:542-51.
8. Cust AE, Schmid H, Maskiell JA, Jetann J, Ferguson M, Holland EA, Agha-Hamilton C, Jenkins MA, Kelly J, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Mann GJ. Population-based, case-control-family design to investigate genetic and environmental influences on melanoma risk: Australian Melanoma Family Study. Am J Epidemiol 2009;170:1541-54.
9. Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, Affleck P, Leake S, Haynes S, Karpavicius B, Marsden J, Gerry E, Bale L, Bertram C, Field H, Barth JH, Silva Idos S, Swerdlow A, Kanetsky PA, Barrett JH, Bishop DT, Bishop JA. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009;45:3271-81.
10. Newton-Bishop JA, Chang YM, Iles MM, Taylor JC, Bakker B, Chan M, Leake S, Karpavicius B, Haynes S, Fitzgibbon E, Elliott F, Kanetsky PA, Harland M, Barrett JH, Bishop DT. Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom. Cancer Epidemiol Biomarkers Prev 2010;19:2043-54.
11. Cannings C, Thompson EA. Ascertainment in the sequential sampling of pedigrees. Clin Genet 1977;12:208-12.
12. Harland M, Goldstein AM, Kukalizch K, Taylor C, Hogg D, Puig S, Badenas C, Gruis N, ter Huurne J, Bergman W, Hayward NK, Stark M, Tsao H, Tucker MA, Landi MT, Scarra GB, Ghiorzo P, Kanetsky PA, Elder D, Mann GJ, Holland EA, Bishop DT, Bishop JN. A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer 2008;44:1269-74.
13. Pjanova D, Engele L, Randerson-Moor JA, Harland M, Bishop DT, Newton Bishop JA, Taylor C, Debniak T, Lubinski J, Kleina R, Heisele O. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population. Melanoma Res 2007;17:185-91.
14. Taylor CF. Mutation scanning using high-resolution melting. Biochem Soc Trans 2009;37:433-7.
15. Lange K, Cantor R, Horvath S, Perola M, Sabatti C, Sinsheimer J, Sobel E. Mendel version 4.0: a complete package for the exact genetic analysis of discrete traits in pedigree and population data sets. Am J Hum Genet 2001;69(Suppl):504.
16. Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer Incidence in Five Continents. Vol. I to VIII. Lyon: IARC, 2005.
17. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. Cancer Incidence in Five Continents. Vol. IX. Lyon: IARC, 2007.
18. Goldstein AM, Falk RT, Fraser MC, Dracopoli NC, Sikorski RS, Clark WH Jr, Tucker MA. Sun-related risk factors in melanoma-prone families with CDKN2A mutations. J Natl Cancer Inst 1998;90:709-11.
19. Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Busam K, From L, Mujumdar U, Wilcox H, Begg CB. The prevalence of CDKN2A germline mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev 2006;15:1520-5.
20. Aitken JF, Youl P, Green A, MacLennan R, Martin NG. Accuracy of case-reported family history of melanoma in Queensland, Australia. Melanoma Res 1996;6:313-17.
21. Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer 1990;46:356-61.
22. Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Newton Bishop JA, Bishop DT, Kanetsky PA, Hayward NK, Gillanders E, Elder DE, Avril MF, Azizi E, van Belle P, Bergman W, Bianchi-Scarra G, Bressac-de Paillerets B, Calista D, Carrera C, Hansson J, Harland M, Hogg D, Hoiom V, Holland EA, Ingvar C, Landi MT, Lang JM, Mackie RM, Mann GJ, Ming ME, Njauw CJ, Olsson H, Palmer J, Pastorino L, Puig S, Randerson-Moor J, Stark M, Tsao H, Tucker MA, van der Velden P, Yang XR, Gruis N. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst 2010;102:1568-83.
23. Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998;11:1-3.